Free Trial

Axsome Therapeutics (AXSM) Stock Price, News & Analysis

Axsome Therapeutics logo
$108.98 -1.75 (-1.58%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$108.21 -0.77 (-0.71%)
As of 07/11/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Axsome Therapeutics Stock (NASDAQ:AXSM)

Key Stats

Today's Range
$108.48
$112.21
50-Day Range
$100.69
$116.49
52-Week Range
$72.21
$139.13
Volume
978,142 shs
Average Volume
668,909 shs
Market Capitalization
$5.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$172.33
Consensus Rating
Buy

Company Overview

Axsome Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
95th Percentile Overall Score

AXSM MarketRank™: 

Axsome Therapeutics scored higher than 95% of companies evaluated by MarketBeat, and ranked 61st out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Axsome Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.06, and is based on 15 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Axsome Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Axsome Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Axsome Therapeutics are expected to grow in the coming year, from ($2.79) to $2.82 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Axsome Therapeutics is -18.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Axsome Therapeutics is -18.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Axsome Therapeutics has a P/B Ratio of 92.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Axsome Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.66% of the float of Axsome Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Axsome Therapeutics has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in Axsome Therapeutics has recently increased by 1.49%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Axsome Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Axsome Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.66% of the float of Axsome Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Axsome Therapeutics has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in Axsome Therapeutics has recently increased by 1.49%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Axsome Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Axsome Therapeutics this week, compared to 11 articles on an average week.
  • Search Interest

    12 people have searched for AXSM on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,834,215.00 in company stock.

  • Percentage Held by Insiders

    22.30% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    81.49% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Axsome Therapeutics' insider trading history.
Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AXSM Stock News Headlines

Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
Axsome Therapeutics Inc News (AXSM) - Investing.com
Axsome Therapeutics (AXSM) Initiated with a Buy at Oppenheimer
Axsome Therapeutics (AXSM) Gets a Buy from Wells Fargo
See More Headlines

AXSM Stock Analysis - Frequently Asked Questions

Axsome Therapeutics' stock was trading at $84.61 on January 1st, 2025. Since then, AXSM stock has increased by 28.8% and is now trading at $108.98.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced its quarterly earnings results on Tuesday, February, 18th. The company reported ($0.96) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.01. The firm had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative trailing twelve-month return on equity of 272.80% and a negative net margin of 64.39%.
Read the conference call transcript
.

Axsome Therapeutics (AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

Top institutional investors of Axsome Therapeutics include Assenagon Asset Management S.A. (0.37%) and Pallas Capital Advisors LLC (0.08%). Insiders that own company stock include Roger Jeffs, Mark Coleman, Nick Pizzie, Mark E Saad, Mark L Jacobson and Hunter R Murdock.
View institutional ownership trends
.

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Axsome Therapeutics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Marinus Pharmaceuticals (MRNS).

Company Calendar

Last Earnings
2/18/2025
Today
7/12/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AXSM
CIK
1579428
Employees
380
Year Founded
N/A

Price Target and Rating

High Price Target
$216.00
Low Price Target
$105.00
Potential Upside/Downside
+58.1%
Consensus Rating
Buy
Rating Score (0-4)
3.06
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($5.77)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$287.22 million
Net Margins
-64.39%
Pretax Margin
-64.37%
Return on Equity
-272.80%
Return on Assets
-36.69%

Debt

Debt-to-Equity Ratio
3.48
Current Ratio
2.03
Quick Ratio
1.96

Sales & Book Value

Annual Sales
$385.69 million
Price / Sales
13.91
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.18 per share
Price / Book
92.36

Miscellaneous

Outstanding Shares
49,240,000
Free Float
38,256,000
Market Cap
$5.37 billion
Optionable
Optionable
Beta
0.46

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:AXSM) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners